Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
2,214,462
-
Shares change
-
+231,556
-
Total reported value, excl. options
-
$130,530,022
-
Value change
-
+$13,765,279
-
Number of buys
-
18
-
Number of sells
-
-18
-
Price
-
$59
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q2 2018
57 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q2 2018.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,214,462 shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (809,089 shares), MEITAV DASH INVESTMENTS LTD (483,079 shares), CITIGROUP INC (200,337 shares), CLS Investments, LLC (147,000 shares), RAYMOND JAMES & ASSOCIATES (91,506 shares), BANK OF AMERICA CORP /DE/ (78,599 shares), MORGAN STANLEY (61,720 shares), SG Americas Securities, LLC (50,000 shares), CITADEL ADVISORS LLC (49,429 shares), and Virtu Financial LLC (34,244 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.